Could Gilead and Galapagos' JAK inhibitor lead the class? Wall Street thinks it has a chance.

Several leading Wall Street analysts are pegging Gilead Sciences and Galapagos' experimental rheumatoid arthritis treatment to emerge as a leader in a market now crowded with therapeutic options. But questions remain about when exactly their drug could reach patients.